Company: TELO
Filing Date: 2025-05-21
Form Type: 8-K
Source: 0001641172-25-011868
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-21
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

Investment
from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1’s upcoming IND submission for
a rare disease indication

On
May 19, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (the “ Company”) raised $3 million in equity financing through
a direct investment by The Bayshore Trust, an entity affiliated with the Company’s largest shareholder.

The
transaction was structured as a straight restricted common stock deal with no warrants, no discounts, and no convertible features. The
Company issued 1 million restricted shares of its common stock, no par value (the “ Common Stock”) at a purchase price of
$3.00 per share, representing an 18% premium to the closing share price of the Common Stock of $2.54 on the date of execution.

This
transaction follows a prior $1 million equity investment at $7.00 per share made on December 9, 2024, through The Starwood Trust - an
entity affiliated with the Company’s largest shareholder - and complements an existing $5 million non-dilutive line of credit
from the same group, which remains undrawn.

Proceeds
from the offering are expected to support regulatory and development activities, including the planned IND submission for Telomir-1 in
a rare disease indication.

The
Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended (the “ Securities Act”),
for the private placement of the equity securities pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D promulgated
thereunder because, among other things, the transaction did not involve a public offering, the recipient is an accredited investor, the
recipient acquired the securities for investment and not resale, and the Company took appropriate measures to restrict the transfer of
the securities.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                    TELOMIR                                       
  Dated:            By:                        /s/                
                    Name:                      Erez               
                    Title:                     Chief